Posted on 19th January 2014
Choroideremia affects about 1 in 50,000 people who see their eye sight deteriorating as the light-detecting cells in their eyes die, usually becoming completely blind during their mid-life – a disease not dissimilar to the more widely known retinitis pigmentosa. There has been lots of research in this area but this is the first real world example of success.
Whilst the long-term effects are still unknown, the fact that the trial has had such early successes is a huge step forward and will give real hope to those suffering from various genetic eye diseases.
And it doesn’t stop there. There are many diseases with genetic components that affect eyesight, such as glaucoma which a number of my patients suffer from, and I am hopeful that the same principle could be used to treat a raft of similar diseases in the future.
What is especially heart-warming, is that the research was funded by the Tommy Salisbury Choroideremia Fund set up by the parents of Tommy, a 13-year-old boy from Kent who was diagnosed with the disease eight years ago. Wouldn’t it be great if he reaped the rewards of the research?
Read more about it here
22nd April 2021
After a year like no other, we are especially impressed by our optometrist, Rebecca Daly, who is one of the first individuals to have gained the NHS Education for Scotland Glaucoma Award Training (NES...Read more
14th April 2021
Myopia is expected to affect 50% of the world population by 2050. In the UK, the amount of myopia has increased from 10% to 23% of children in the past 50 years. In the past year, we have noticed an i...Read more